Inside Nephrology: A Weekly Review
Nefrologia
AI in Urology: Game-Changer or Human-Touch Risk?
Explore how artificial intelligence is reshaping urology—from precision diagnostics and virtual consultations to novel cancer imaging—while raising new questions about the future of patient care.
Bibliography
- McSweeney ST, Werneburg GT, Vasavada SP. Artificial intelligence in the business of urology. Urology. 2025 Sep;203:83-85. doi:10.1016/j.urology.2025.04.059.
- Feitz W, Battye M, Wu HY, Fossum M. The European Reference Network eUROGEN: interview. J Pediatr Urol. 2025 Aug 21:S1477-5131(25)00447-4. doi:10.1016/j.jpurol.2025.08.020.
- Hayes B et al. Patient-related outcomes for interstitial cystitis/bladder pain syndrome: recommendations for trials and practice. Neurourol Urodyn. 2025 Sep;44(7):1455-65. doi:10.1002/nau.70107.
- Zhang Y et al. Global clinical trial landscape and therapeutic trends in bladder cancer: systematic analysis. Int J Surg. 2025 Sep;111(9):6449-52. doi:10.1097/JS9.0000000000002662.
- Feijó M et al. Endocrine-disrupting chemicals as prostate carcinogens. Nat Rev Urol. 2025 Sep;22(9):609-31. doi:10.1038/s41585-025-01031-9.
- Wei Y et al. Programmed cell death in cancer. MedComm (2020). 2025 Aug;6(9):e70357. doi:10.1002/mco2.70357.
- Calleja Duran I et al. Urinary bladder paraganglioma: an unusual entity. J Med Cases. 2025 Aug;16(8):287-92. doi:10.14740/jmc5145.
- Flores HA et al. Management of pediatric testicular microlithiasis. Front Pediatr. 2025 Aug;13:1588261. doi:10.3389/fped.2025.1588261.
- Lowentritt B et al. Doublet or triplet therapy in metastatic hormone-sensitive prostate cancer in U.S. community urology. Urol Pract. 2025 Sep;12(5):533-40. doi:10.1097/UPJ.0000000000000841.
- Pabst KM et al. [68Ga]Ga-FAPI-46 PET accuracy for cancer imaging: phase 2 trial with histopathology validation. Lancet Oncol. 2025 Sep;26(9):1204-14. doi:10.1016/S1470-2045(25)00299-2.
